Bacterial Antigen Ingredients TRIZ Cases

Multi-epitope peptide vaccines using signal peptides bind diverse MHC alleles, resolving limited population coverage in intracellular pathogen defense.

Truncated diphtheria toxin derivatives bind overexpressed HB-EGF in atherosclerotic plaques, reducing stenosis while minimizing systemic hypersensitivity risks.

Aligning transgene codons with viral late gene patterns improves temporal regulation and immune response magnitude.

Oral Lactococcus lactis JCM5805 resolves adjuvant safety trade-offs by boosting specific CTL and antibody responses without harmful side effects.

A bacterial ClpB protein mimics alpha-MSH to stimulate appetite-regulating antibodies.

Antibody nanovalves on mesoporous silica nanoparticles block cargo diffusion until pathogen binding triggers release, reducing off-target antibiotic toxicity.

Human microbiota bacteria induce cross-reactive antibodies against the SARS-CoV-2 spike protein.

Targeted gene deletions reduce virulence while maintaining immunogenicity to lower mortality rates.

Bacterial fermentation incorporates azido groups into capsular polysaccharides, avoiding laborious chemical modification that damages immunogenicity.

Vaccine composition uses non-toxic alpha toxin domains to stimulate immune responses, reducing mortality and disease severity in poultry.

Patient-selected immunomodulatory kits convert leukemic blasts into dendritic cells, activating T-cells without inducing proliferation.

Discrete apertures direct fluid jets into a vaporization chamber conduit, promoting turbulence that prevents carbon dioxide crystal clumping.

An Ehrlichia sonicate vaccine composition elicits a protective immune response against infection.

Intranasal nonreplicating adenovirus vaccines bypass injection fears and adverse side effects while eliciting rapid, prolonged mucosal protection.

A vaccine composition combines immunogenic polypeptides, adenoviral vectors, and an adjuvant administered concomitantly.

Targeting conserved rpsA genes induces hyper-blebbing across diverse species, resolving variability limits in large-scale vaccine production.

Chromosomal antigen integration distributes expression cassettes across multiple sites, resolving metabolic stress and maintaining bacterial fitness.

Isolating specific protein fractions from tuberculosis mycobacterium activates killer cells, resolving low antibody titers in calves.

Temperature-sensitive plasmids eliminate antibiotic resistance genes while maintaining auxotrophic Listeria vaccine strains.

A vaccine containing inactivated Staphylococcus aureus and Streptococcus uberis strains stimulates local udder immunity.

High shear mixing hydrates lipid powders to form stable cationic liposomes without organic solvents.

Psoralen-modified killed protozoans stimulate targeted immunity, reducing parasite infectivity and pathology in vertebrate hosts.

Combining consensus and primary isolate plasmids resolves the trade-off between cellular immunity and antibody titers in HIV immunization.

Enterococcus gallinarum flagellin polypeptides stimulate strong TLR5 immune responses.

Squalane and vitamin E-acetate adjuvants resolve virucidal conflicts in combination vaccines, reducing mortality and respiratory disease.

Specific antigenic polypeptides reduce frequent booster injection requirements while maintaining consistent protection against tick infestation.

Lactobacillus salivarius PS7 strain reduces acute otitis media episodes, avoiding antibiotic resistance and microbiota disturbance.

CRISPR-modified bacteria secrete therapeutic compounds to inhibit cancer cell growth and delay disease onset.

Anti-CD28 and anti-CD49d antibodies enhance ELISpot sensitivity for latent tuberculosis detection, resolving false negatives in standard IGRA tests.

A feed composition containing Bacillus subtilis, Bacillus pumilus, and Bacillus licheniformis strains enhances shrimp immunity and growth rates.

Specific amino acid residue changes in T-cell epitopes and vascular leak syndrome motifs lower immune responses while preserving therapeutic efficacy.

Recombinant VMP-like proteins address diagnostic complexity by enabling specific detection of Borrelia antigens through targeted antibody binding.

Virus-like particles conjugate polysaccharides to deliver multiple antigens, resolving protein overload and misfolding in multivalent vaccines.

A low dose volume vaccine composition induces antibody immune responses in human subjects.

Botulinum neurotoxins block neurosecretory substances to reduce vascular perfusion and address the limited efficacy of topical creams.

A CspZ peptide conjugated to bacteriophage Qβ virus-like particles induces robust antibody responses against Borrelia burgdorferi.

LPS O-antigen serotyping differentiates pathogenic E. coli strains to predict renal scarring risk and reduce unnecessary antibiotic exposure.

Photonuclear transmutation of zinc-68 targets yields high-purity copper-67 without reactor waste or complex mechanical retrieval systems.

Engineers apply parameter changes to BCG, creating a recombinant strain that competes with drug-resistant Mtb to shorten treatment cycles.

Maternal vaginal microbiota inoculum administration restores normal microbial colonization in pre-term and C-section born infants, reducing disease risks.

Specific residue mutations in mutant Clostridium difficile toxins A and B reduce host cell cytotoxicity while preserving immunogenic epitopes.

Streptolysin O administration reduces hippocampal inflammation and restores memory in traumatic brain injury cases.

Aluminium hydroxide and monophospholipid A potentiate local immune responses to clear established infections.

Combining PCR speed with serology specificity resolves the tradeoff between early diagnosis and accurate confirmation of active infection.

Nanoemulsion stabilizes recombinant protective antigen for durable anthrax immunity.

Deleting the fcp1 gene creates a motility-deficient Leptospira strain that reduces infectious disease risk by attenuating bacterial virulence.

Nucleoside-modified RNA resolves mRNA stability and immunogenicity trade-offs by reducing innate immune activation to enable robust adaptive immunity.